Warning: Undefined variable $page_cluster_id in /home3/thegood9/public_html/website_70aad9ea/header.php on line 29



Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Monday, April 20, 2026




In Detail Full day, Monday, April 20, 2026, Timezone: America/Chicago


Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial

Omar Nadeem / nature - Nature Medicine, Published online: 20 April 2026; doi:10.1038/s41591-026-04365-yAs presented at the 2026 AACR Annual Meeting, in a phase 2 trial, treatment of patients with high-risk smoldering multiple myeloma with BCMA-targeting CAR T cell therapy cilta…

AI Summary: The CAR-PRISM phase 2 study reports that ciltacabtagene autoleucel, a BCMA-directed CAR T therapy, produced meaningful responses in patients with high‑risk smoldering multiple myeloma, suggesting potential to delay progression to symptomatic disease and defer immediate treatment. Early results show promising efficacy with manageable toxicities, hinting at a shift toward treating disease earlier rather than later.

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials

CAR-PRISM results: compelling MRD negativity, potential treatment shift


Experts weigh in: praise, safety concerns, and clinical enthusiasm

5 wks / oncodaily

5 wks / oncodaily

5 wks / oncodaily

5 wks / oncodaily


Policy and IO context: regulation, immune engineering, industry implications

5 wks / oncodaily

5 wks / oncodaily

5 wks / oncodaily


All Other Stories

29 days / oncodaily

29 days / oncodaily

4 wks / oncodaily

4 wks / oncodaily

4 wks / nature

4 wks / oncodaily

5 wks / oncodaily

5 wks / oncodaily

5 wks / oncodaily


Back to Top / Monday, April 20, 2026, 6:24 pm / permalink 22505 / 27 stories in 5 wks /

Bruce the parrot is missing his upper beak —‬ but that hasn't stopped him from becoming an undefeated jousting champion

livescience - A kea parrot in New Zealand who lost the top part of his beak when young has developed a new way to fight other males that has made him unbeatable.

AI Summary: Bruce, a parrot missing his upper beak, maintains top social rank by using an inventive "jousting" maneuver during conflicts. Avian behaviorists are both amused and impressed: despite a major physical handicap, Bruce’s behavioral adaptation secures resources and dominance — a tidy lesson in resilience and evolutionary improvisation.

#wildlife #animalhealth

5 wks / livescience


Back to Top / Monday, April 20, 2026, 5:25 pm / permalink 22499 / 6 stories in 5 wks /

Long-term Use of Immunotherapy May Be Safe for Patients With Alveolar Soft Part Sarcoma

Kathleen Medora / aacr - SAN DIEGO – Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard two years, according to results from …

AI Summary: Observational data indicate extended checkpoint inhibitor therapy can be tolerated by patients with alveolar soft part sarcoma and may provide sustained disease control for many. The findings support considering prolonged treatment in select cases, while underscoring the need for vigilant monitoring for late toxicities and randomized trials to confirm benefit.

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials

4 wks / esmo

5 wks / oncodaily

5 wks / oncodaily


Back to Top / Monday, April 20, 2026, 5:25 pm / permalink 22498 / 9 stories in 5 wks /

Baby food brand HiPP recalls jars in Austria after samples test positive for rat poison

abcnews - HiPP is recalling some baby food jars in Austria after samples tested positive for rat poison in Austria, Slovakia and the Czech Republic

AI Summary: Austrian health authorities have ordered a recall of specific HiPP baby food jars after lab tests detected contamination with a rodent poison. Retailers pulled the affected batches, parents are being urged to check product codes and discard implicated jars, and investigators are tracing how the contamination occurred while monitoring for any reported illnesses.

#publichealth #governmentpolicy #foodsafety #productrecall #infanthealth #supplychain #nutrition

4 wks / abcnews

5 wks / abcnews


Back to Top / Monday, April 20, 2026, 4:21 am / permalink 22456 / 6 stories in 5 wks /

Lyrid meteor shower 2026: See spring's first rain of 'shooting stars' peak in moonless skies

livescience - Expect bright fireballs during the Lyrid meteor shower, which will peak in moonless skies on April 22, 2026.

AI Summary: The Lyrid meteor shower reaches its spring peak in moonless skies, giving skywatchers a chance to spot a steady stream of meteors. Best viewing is away from city lights on the peak nights, no telescope required—just patience, a blanket and realistic expectations. It’s nature’s modest, low‑budget fireworks display.

#none

5 wks / livescience

5 wks / livescience

5 wks / livescience

6 wks / livescience


Back to Top / Monday, April 20, 2026, 12:24 am / permalink 22448 / 8 stories in 5 wks /

Improving oral care more than halves hospital-acquired pneumonia risk, major trial finds

medicalxpress - A landmark trial presented at ESCMID Global 2026 shows that improving oral hygiene for hospital patients can reduce the risk of non-ventilator-associated hospital-acquired pneumonia (NV-HAP) by 60%.

AI Summary: A major randomized trial found that simple improvements in oral care—regular toothbrushing and mouth hygiene—cut hospital‑acquired pneumonia risk by over half in hospitalized patients. The low‑cost intervention reduced respiratory complications and antibiotic use, suggesting wards could prevent serious infections with a toothbrush rather than another headline‑seeking drug.

#healthcare #publichealth #hospitaloperations #infectiousdisease #clinicaltrials

4 wks / newscientist

6 wks / newscientist


Back to Top / Monday, April 20, 2026, 12:23 am / permalink 22447 / 4 stories in 5 wks /

Zoldonrasib Shows Early Strength in Previously Treated KRAS G12D NSCLC

oncodaily - KRAS G12D has long been one of the most frustrating targets in thoracic oncology. It is biologically important, clearly druggable in theory, and yet patients with KRAS G12D-mutant non-small cell […]

AI Summary: Investigational KRAS(ON) inhibitor zoldonrasib produced effective, durable responses in patients with advanced KRAS G12D–mutated non‑small‑cell lung cancer after prior therapy. Early‑phase data show meaningful tumour shrinkage and a manageable safety profile, offering a targeted option for a mutation long considered untargetable and breathing new life into KRAS drug development.

#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials

Experts on site: RAS inhibitors reshape NSCLC treatment landscape

5 wks / oncodaily

5 wks / oncodaily

5 wks / oncodaily

5 wks / oncodaily

5 wks / oncodaily


Industry moves: BridgeBio reshuffles as KRAS race heats up


On the AACR floor: zoldonrasib delivers durable G12D responses

5 wks / oncodaily

6 wks / oncodaily


Perioperative and biomarker research reshapes precision care in NSCLC

5 wks / oncodaily

5 wks / nature

5 wks / oncodaily

5 wks / oncodaily


All Other Stories

4 wks / oncodaily

4 wks / oncodaily

5 wks / oncodaily

5 wks / oncodaily

5 wks / oncodaily


Back to Top / Monday, April 20, 2026, 12:23 am / permalink 22446 / 20 stories in 5 wks /



StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Vaccine Safety, Supplements, Rural Health, Oncology and look for the RSS link.

More StackHealth





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.